leisure time -WSS

leisure time

author：explore 2025-09-10 16:44:55 - browse：294

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Report captures long Covid’s disabling effects and policy challenges

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

5 takeaways from STAT's examination of Zynex Medical

STAT Summit: How researchers deal with rejection

Moderna says combo Covid

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Virtual Event: ASCO Recap, Live!

Wikipedia

leisure time

knowledge

Jerome Adams on the need for new antivirals for Covid

'Essentially witchcraft:' A former naturopath takes on the field

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Duchenne breakthrough therapy leaves behind pioneering families

Results on Novartis prostate cancer therapy could expand its use

Drug repurposing or repositioning? The language matters

Smaller biotechs seek to piggyback on weight loss drug boom

Medicare details structure of new drug price negotiation program

STAT Readout: Friday, Oct. 20 biotech updates

focus

CZI to create biohub to build anti

Cigna wins case to block Amy Bricker's move to CVS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Readers discuss the intersection of pregnancy and addiction

STAT Summit: The economic case for universal basic health care

Health tech investors get more selective as pandemic boom fades

knowledge

entertainment

hotspot

explore